An evaluation and an examination of the optimization of the cancer immunotherapy for advanced non-small cell lung cancer

An evaluation and an examination of the optimization of the cancer immunotherapy for advanced non-small cell lung cancer - IOB-LC1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031127

Enrollment

Registered

2018-02-05

Start date

2018-02-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with advanced non-small cell lung cancer who are going to receive a therapy with immune checkpoint Inhibitors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with advanced non-small-cell lung cancer Patients who are going to receive immunity checkpoint inhibitors Written informed consent is obtained from all the patients.

Exclusion criteria

Exclusion criteria: Patients having an overlap cancer with activity Patients that an doctor judged to be inappropriate

Design outcomes

Primary

Measure	Time frame
We examine the immunoreaction with the immune checkpoint inhibitor and the association of the clinical response.	—

Countries

Japan

Contacts

Public ContactNaruo Yoshimura

Tohoku Medical and Pharmaceutical University Department of pulmonology

y-naruo@sc4.so-net.ne.jp022-259-1221

Outcome results